AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)

被引：1

作者：

Diakite, I ^{[1
]}

Lin, V. W. ^{[2
]}

Klijn, S. ^{[3
]}

Navale, L. ^{[2
]}

Purdum, A. G. ^{[2
]}

Fenwick, E. ^{[4
]}

Botteman, M. ^{[1
]}

van Hout, B. ^{[5
]}

机构：

[1] Pharmerit Int, Bethesda, MD USA

[2] Kite, Santa Monica, CA USA

[3] Pharmerit Int, Rotterdam, Netherlands

[4] Pharmerit Int, Oxford, England

[5] Univ Sheffield, Sheffield, S Yorkshire, England

来源：

VALUE IN HEALTH | 2019年 / 22卷

关键词：

D O I：

10.1016/j.jval.2019.04.050

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

MS2

引用

页码：S41 / S41

页数：1

共 50 条

[41] Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction
Locke, Frederick L.
Jacobson, Caron
Ma, Long
Dong, Hua
Hu, Zhen-Huan
Siddiqi, Tanya
Ahmed, Sairah
Ghobad, Armin
Miklos, David B.
Lin, Yi
Perales, Miguel-Angel
Lunning, Matthew A.
Herr, Megan M.
Hill, Brian T.
Ganguly, Siddhartha
Mirza, Abu-Sayeef
Nikiforow, Sarah
Xu, Hairong
Pasquini, Marcelo C.
BLOOD, 2021, 138
[42] Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
Jacobson, Caron
Locke, Frederick L.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre H.
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Rossi, John M.
Bot, Adrian
Zheng, Lianqing
Vezan, Remus
Bashir, Zahid
Kim, Jenny J.
Chu, Rong
Neelapu, Sattva S.
BLOOD, 2020, 136
[43] Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison
Neelapu, Sattva Swarup
Maloney, David G.
Salles, Gilles A.
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
Abramson, Jeremy S.
Kamdar, Manali
Liu, Fei Fei
Crotta, Alessandro
Previtali, Alessandro
Klijn, Sven L.
Wang, Pearl
Situ, Aaron
Zhang, Yixie
Bonner, Ashley
Lunning, Matthew A.
BLOOD, 2022, 140 : 4655 - 4656
[45] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick M.
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van Den Neste, Eric
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny J.
Gisselbrecht, Christian
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S232 - S232
[46] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Erin
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny
Gisselbrecht, Christian
MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576
[47] Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Locke, Frederick L.
Chou, Justin
Vardhanabhuti, Saran
Perbost, Regis
Dreger, Peter
Hill, Brian T.
Lee, Catherine
Zinzani, Pier Luigi
Kroeger, Nicolaus
Lopez-Guillermo, Armando
Greinix, Hildegard
Zhang, Wangshu
Tiwari, Gayatri
To, Christina Ann
Cheng, Paul C.
Bot, Adrian
Shen, Rhine
Filosto, Simone
Galon, Jerome
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
Ahmed, Sairah
Furqan, Fateeha
Strati, Paolo
Westin, Jason
Fayad, Luis
Hagemeister, Frederick B.
Lee, Hun Ju
Iyer, Swaminathan Padmanabhan
Nair, Ranjit
Nastoupil, Loretta J.
Parmar, Simrit
Rodriguez, Maria Alma
Samaniego, Felipe
Steiner, Raphael
Wang, Michael
Pinnix, Chelsea Camille
Flowers, Christopher
Horowitz, Sandra B.
Hawkins, Misha
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Vose, Julie M.
Lin, Yi
Budde, Lihua E.
Maloney, David G.
Jaglowski, Samantha
Riedell, Peter A.
Lekakis, Lazaros J.
Perales, Miguel-Angel
Kim, Jenny J.
Kawashima, Jun
Yang, Yin
Rossi, John M.
Goyal, Lovely
Neelapu, Sattva S.
BLOOD, 2020, 136
[50] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David Bernard
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →